|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Ezrin (EZR) antibody
|Synonyms||CVL, CVIL, VIL2, MGC1584, FLJ26216, DKFZp762H157, EZR, vil2, wu:fc05c03, wu:fj31d06, cvl, cvil, MGC97499|
Alternatives ELISA, Western Blotting (WB)
|5 references available|
|Price||450.00 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 2 to 3 Business Days|
|Immunogen||VIL2 (AAH13903, 1 a.a. ~ 587 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 K|
|Description||Other names: CVIL, CVL, DKFZp762H157, MGC1584 villin 2 (ezrin)|
|Characteristics||Purified Mouse Monoclonal Antibody (Mab)|
|Specificity||VIL2 (AAH13903, 1 a.a. ~ 587 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Molecular Weight||69413 DA|
Background: The cytoplasmic peripheral membrane protein encoded by this gene functions as a protein-tyrosine kinase substrate in microvilli. As a member of the ERM protein family, this protein serves as an intermediate between the plasma membrane and the actin cytoskeleton. This protein plays a key role in cell surface structure adhesion, migration and organization, and it has been implicated in various human cancers. A pseudogene located on chromosome 3 has been identified for this gene. Alternatively spliced variants have also been described for this gene.
|Application Notes||ELISA ~~ 1ug/ml~3ng/ml Western blot ~~ 1:500~1000|
|Buffer||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles|
|Research Area||Phospho-specific antibodies, Protein Modifications, Cell Structure, Cancer|
|Restrictions||For Research Use only|
|VIL2 monoclonal antibody (M04), clone 1E11. Western Blot analysis of VIL2 expression in HepG2 ( Cat # L019V1 ).|
Machado, Navarro, Giner et al.: "Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors." in: Virchows Archiv : an international journal of pathology, Vol. 457, Issue 1, pp. 87-9, 2010 (PubMed).
Boldrini, Peres, Morini et al.: "Immunoexpression of Ezrin and CD44 in patients with osteosarcoma." in: Journal of pediatric hematology/oncology, Vol. 32, Issue 6, pp. e213-7, 2010 (PubMed).
Bailey, Xie, Do et al.: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).
Johnatty, Beesley, Chen et al.: "Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot"." in: PLoS genetics, Vol. 6, Issue 7, pp. e1001016, 2010 (PubMed).
Tuna, Yorukoglu, Mazzucchelli et al.: "Ezrin immunoreactivity in renal cell carcinomas." in: Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology, Vol. 31, Issue 5, pp. 340-4, 2010 (PubMed).